Table 7.
Comparison of the characteristics at baseline between the cohort of patients treated with the elotuzumab, pomalidomide and dexamethasone triple regimen in the real-world setting and those enrolled in the ELOQUENT-3 clinical trial.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.